Strs Ohio Takes $366,000 Position in Castle Biosciences, Inc. $CSTL

Key Points

• Strs Ohio has acquired a new position in Castle Biosciences, purchasing 18,300 shares valued at approximately $366,000 during the 1st quarter.
• Castle Biosciences reported $0.15 earnings per share for the last quarter, significantly exceeding the estimated loss of ($0.51), and had a revenue of $86.18 million compared to the expected $71.53 million.
• The company has seen recent upgrades by analysts, with Canaccord Genuity setting a target price of $37.00 and Zacks lifting its rating from "strong sell" to "hold."

Strs Ohio purchased a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 18,300 shares of the company's stock, valued at approximately $366,000. Strs Ohio owned about 0.06% of Castle Biosciences at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of CSTL. Harbour Investments Inc. bought a new stake in shares of Castle Biosciences in the 1st quarter valued at approximately $50,000. Jones Financial Companies Lllp boosted its stake in Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock valued at $54,000 after buying an additional 2,648 shares in the last quarter. Amundi grew its position in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company's stock valued at $79,000 after acquiring an additional 4,111 shares during the period. CWM LLC raised its stake in Castle Biosciences by 835.0% during the first quarter. CWM LLC now owns 4,142 shares of the company's stock worth $83,000 after acquiring an additional 3,699 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Castle Biosciences by 1,865.8% during the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company's stock worth $87,000 after acquiring an additional 4,142 shares in the last quarter. Institutional investors own 92.60% of the company's stock.

Castle Biosciences Trading Down 2.2%

Shares of CSTL opened at $23.56 on Wednesday. The business's fifty day moving average is $20.26 and its 200-day moving average is $19.40. The firm has a market cap of $683.48 million, a price-to-earnings ratio of -67.31 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.69 and a current ratio of 6.85. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.66. The company had revenue of $86.18 million for the quarter, compared to analysts' expectations of $71.53 million. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%. Castle Biosciences has set its FY 2025 guidance at EPS. Equities analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CSTL shares. Zacks Research raised shares of Castle Biosciences from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Canaccord Genuity Group reiterated a "buy" rating and set a $37.00 target price on shares of Castle Biosciences in a research report on Tuesday, September 9th. Finally, Wall Street Zen raised Castle Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday, August 10th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

Insider Activity at Castle Biosciences

In related news, insider Derek J. Maetzold sold 1,339 shares of the company's stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $21.97, for a total transaction of $29,417.83. Following the completion of the sale, the insider owned 65,666 shares in the company, valued at approximately $1,442,682.02. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.